Tarsus Pharmaceuticals Announces Acquisition of Alkeus Pharmaceuticals

What Happened
Tarsus Pharmaceuticals announced it completed its acquisition of Alkeus Pharmaceuticals on September 4, 2026, pursuant to a Merger Agreement dated July 31, 2026. Merger Sub merged into Alkeus, leaving Alkeus as a wholly owned subsidiary of Tarsus. Tarsus paid upfront consideration of $270,000,000 in cash (subject to customary adjustments) and issued 2,908,692 shares of its common stock (par value $0.0001) to Alkeus equityholders. The company also filed a press release announcing the closing.

Key Details

• Closing date: September 4, 2026; Merger Agreement dated July 31, 2026.
• Up-front consideration: $270,000,000 cash (subject to adjustments) plus 2,908,692 shares of Tarsus common stock.
• Contingent payments: up to $350,000,000 in milestone payments (including $250,000,000 payable in cash and/or shares upon U.S. regulatory approval and $100,000,000 payable in cash upon first U.S. sale).
• Ongoing obligations: tiered revenue-sharing payments in the low-to-mid single digits on future worldwide net sales of gildeuretinol (with certain reductions).
• Additional agreements: certain Alkeus equityholders executed joinders and a registration rights agreement that became effective at closing; the company attached the Merger Agreement and related forms as exhibits and issued a press release (Exhibit 99.1).

Why It Matters
This acquisition represents a material use of Tarsus's capital and stock: $270M cash outlay (subject to adjustment) plus issuance of nearly 2.9M shares up front, with up to $350M of further contingent liabilities tied to regulatory and commercial milestones. Investors should note both the potential upside (addition of Alkeus’s assets and any future product revenues) and the concrete near-term impacts: cash deployment, share issuance (dilution), and future payment obligations including revenue sharing on gildeuretinol sales. The registration rights and related agreements may affect future share liquidity and resale by former Alkeus holders.